Darren Brown

Dr. Brown joined Inhibrx in 2019 and is responsible for analytical development and quality control for their early and late-stage clinical programs. He brings over 18 years of biopharmaceutical industry experience in analytical development, quality control, and characterization of antibody and fusion protein-based therapeutics, viral vector-based vaccines, and cell-based therapeutics.

Prior to joining Inhibrx, Dr. Brown was Director of Analytical Operations for biologics at Gilead Sciences and managed CMC activities related to analytical development, product characterization, and quality control for multiple early and late-stage clinical programs. Prior to Gilead Sciences, Dr. Brown led technical teams at Illumina, Genentech, and Biogen in various roles, supporting innovative new product development and managing CMC analytical activities for dozens of novel biologics in clinical development. Dr. Brown received his B.S. in Microbiology and Molecular Genetics from UCLA and his Ph.D. in Biological Chemistry from the UCLA School of Medicine. He conducted postdoctoral studies at the Sanford Burnham Prebys Medical Discovery Institute in La Jolla.